Filing Flows › Gilead Sciences (GILD) › Q3 2025
Gilead Sciences (GILD) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
Gilead Sciences (GILD) reported revenue of $7.8B for the third quarter 2025 (Q3 2025), +3% from a year earlier and +10% from the quarter before. Operating margin was 42.8%, net earnings $3.1B (39.3% of revenue).
Gilead Sciences, Q3 2025: revenue $7.8B (+3% year over year), operating margin 42.8%, net earnings $3.1B, operating cash flow $4.1B. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.8B | +10% | +3% |
| Operating profit | $3.3B | +34% | +275% |
| Net earnings | $3.1B | +56% | +144% |
| Operating cash flow | $4.1B | +397% | -5% |
| Free cash flow | $4.0B | — | -5% |
What changed
Revenue was $7.8B in Q3 2025, up 3% year over year and up 10% from the previous quarter. Biktarvy was the largest line at 47% of revenue. Royalty, contract and other revenues added $0.39B year over year (up 1313%), 176% of the total change. Genvoya declined 16%.
Operating profit was $3.3B, a 42.8% margin (up 31.1 points year over year). Of the extra revenue versus a year earlier, 1089% reached operating profit, above the 12% margin then. Total costs fell 33% while revenue rose 3%. Net earnings were $3.1B, up 144% year over year. The effective tax rate was 16.2%.
Operating cash flow was $4.1B (down 5% year over year), 135% of net earnings. Non-cash charges added back $0.09B of depreciation and $0.23B of share-based compensation. Working capital and other items added $0.74B. After purchases of property, plant and equipment ($0.15B), free cash flow as the company reports it was $4.0B.
Questions
What was Gilead Sciences' revenue in the third quarter 2025?
Gilead Sciences (GILD) reported revenue of $7.8B for the third quarter 2025 (Q3 2025), +3% from a year earlier and +10% from the quarter before.
Was Gilead Sciences profitable in the third quarter 2025?
Operating profit was $3.3B (42.8% of revenue) and net earnings $3.1B.
Source: Gilead Sciences 10-Q on SEC EDGAR.